Is Vyome Holdings, Inc (HIND) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2023
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 19.1% / 30% | 0.1% / 30% | 0.4% / 30% | 51.08% / 5% | ✗ NOT HALAL |
| DJIM | 19.1% / 33% | 0.1% / 33% | 0.4% / 33% | 51.08% / 5% | ✗ NOT HALAL |
| MSCI | 212.3% / 33% | 1.2% / 33% | 4.7% / 33% | 51.08% / 5% | ✗ NOT HALAL |
| S&P | 19.1% / 33% | 0.1% / 33% | 0.4% / 33% | 51.08% / 5% | ✗ NOT HALAL |
| FTSE | 212.3% / 33% | 1.2% / 33% | 4.7% / 50% | 51.08% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 68.4% | |
| Operating Margin | -3707.4% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -43.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$563,983 |
| Free Cash Flow | -$563,983 |
| Total Debt | $3M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 2.0 |
| Total Assets | $1M |
Price & Trading
| Last Close | $2.20 |
| 50-Day MA | $2.65 |
| 200-Day MA | $6.04 |
| Avg Volume | 900K |
|
52-Week Range
$1.75
| |
About Vyome Holdings, Inc (HIND)
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vyome Holdings, Inc (HIND) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vyome Holdings, Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vyome Holdings, Inc's debt ratio?
Vyome Holdings, Inc's debt ratio is 19.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 212.3%.
What are Vyome Holdings, Inc's key financial metrics?
Vyome Holdings, Inc has a market capitalization of $15M, and revenue of $415,940.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.